PDF(Pubmed)
Abstract：
UNASSIGNED: The Accelerating Medicines Partnership Schizophrenia (AMP SCZ) funds a longitudinal study of 43 research sites across 5 continents to develop tools to stratify developmental trajectories of youth at clinical high risk for psychosis (CHR) and identify homogenous targets for future clinical trials. However, there are no sites in Africa, leaving a critical gap in our knowledge of clinical and biological outcomes among CHR individuals.
UNASSIGNED: We describe the development of the Kenya Psychosis-Risk Outcomes Study (KePROS), a 5-year NIH-funded project in Kenya designed to harmonize with AMP SCZ. The study will recruit over 100 CHR and 50 healthy participants and conduct multiple clinical and biomarker assessments over 2 years. Capacity building is a key component of the study, including the construction of an electroencephalography (EEG) laboratory and the upgrading of a local 3 T magnetic resonance imaging (MRI) machine. We detail community recruitment, study methodologies and protocols, and unique challenges with this pioneering research in Africa.
UNASSIGNED: This paper is descriptive only. Planned future analyses will investigate possible predictors of clinical outcomes and will be compared to results from other global populations.
UNASSIGNED: KePROS will provide the research community with a rich longitudinal clinical and biomarker dataset from an African country in the developing Global South, which can be used alongside AMP SCZ data to delineate CHR outcome groups for future treatment development. Training in mental health assessment and investment in cutting-edge biomarker assessment and other technologies is needed to facilitate the inclusion of African countries in large-scale research consortia.
UNASSIGNED: We describe the development of the Kenya Psychosis-Risk Outcomes Study (KePROS), a 5-year NIH-funded project in Kenya designed to harmonize with AMP SCZ. The study will recruit over 100 CHR and 50 healthy participants and conduct multiple clinical and biomarker assessments over 2 years. Capacity building is a key component of the study, including the construction of an electroencephalography (EEG) laboratory and the upgrading of a local 3 T magnetic resonance imaging (MRI) machine. We detail community recruitment, study methodologies and protocols, and unique challenges with this pioneering research in Africa.
UNASSIGNED: This paper is descriptive only. Planned future analyses will investigate possible predictors of clinical outcomes and will be compared to results from other global populations.
UNASSIGNED: KePROS will provide the research community with a rich longitudinal clinical and biomarker dataset from an African country in the developing Global South, which can be used alongside AMP SCZ data to delineate CHR outcome groups for future treatment development. Training in mental health assessment and investment in cutting-edge biomarker assessment and other technologies is needed to facilitate the inclusion of African countries in large-scale research consortia.
摘要：
■加速药物合作精神分裂症（AMPSCZ）资助了对5大洲43个研究站点的纵向研究，以开发工具对处于临床精神病高风险（CHR）的年轻人的发育轨迹进行分层，并确定未来临床试验的同质目标。然而,非洲没有网站，在CHR个体中，我们对临床和生物学结果的认识存在重大差距。
■我们描述了肯尼亚精神病风险结果研究（Kepros）的发展，在肯尼亚，NIH资助的一个为期5年的项目旨在与AMPSCZ协调。该研究将招募超过100名CHR和50名健康参与者，并在2年内进行多项临床和生物标志物评估。能力建设是研究的重要组成部分,包括脑电图（EEG）实验室的建设和本地3T磁共振成像（MRI）机的升级。我们详细介绍了社区招聘，研究方法和协议，以及非洲这项开创性研究的独特挑战。
■本文仅是描述性的。计划中的未来分析将调查临床结果的可能预测因素，并将与其他全球人群的结果进行比较。
■Kepros将为研究界提供丰富的纵向临床和生物标志物数据集，该数据集来自发展中的全球南部非洲国家，它可以与AMPSCZ数据一起使用，以描绘CHR结果组，用于未来的治疗发展。需要进行心理健康评估方面的培训以及对尖端生物标志物评估和其他技术的投资，以促进非洲国家加入大型研究联盟。
■我们描述了肯尼亚精神病风险结果研究（Kepros）的发展，在肯尼亚，NIH资助的一个为期5年的项目旨在与AMPSCZ协调。该研究将招募超过100名CHR和50名健康参与者，并在2年内进行多项临床和生物标志物评估。能力建设是研究的重要组成部分,包括脑电图（EEG）实验室的建设和本地3T磁共振成像（MRI）机的升级。我们详细介绍了社区招聘，研究方法和协议，以及非洲这项开创性研究的独特挑战。
■本文仅是描述性的。计划中的未来分析将调查临床结果的可能预测因素，并将与其他全球人群的结果进行比较。
■Kepros将为研究界提供丰富的纵向临床和生物标志物数据集，该数据集来自发展中的全球南部非洲国家，它可以与AMPSCZ数据一起使用，以描绘CHR结果组，用于未来的治疗发展。需要进行心理健康评估方面的培训以及对尖端生物标志物评估和其他技术的投资，以促进非洲国家加入大型研究联盟。
